Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis

Stopped earlyPhase 2Relapsing MS2006-002633-20

What it found

Stopped

The trial ended early for another reason (see below).

What was tested

Treatment tested

  • Firategrast

    Integrin alpha-4/beta-1 antagonist|Integrin alpha-4/beta-7 antagonist

What it measured

Main measures

  • The primary endpoint is the cumulative number of new gadolinium-enhancing lesions on monthly MRI scans. MRI is an accepted surrogate marker of MS burden of disease for exploratory trials.

    MRI lesions

Who could take part

Relapsing MS

Show the full criteria

Inclusion criteria

Inclusion: 1. Written informed consent Exclusion: 1. Subjects receiving corticosteroids within 4 weeks of Screening for treatment of MS. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator after discussion with the GSK medical monitor

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

• To investigate the MRI efficacy of six months' administration of Firategrast in subjects with relapsing-remitting MS

Loading reviews and guidelines…

Related trials

History

    1. Started

      Aug 2006

    Assembled by software from public sources.